ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs and rheumatoid arthritis (RA)"

  • Abstract Number: 1468 • 2013 ACR/ARHP Annual Meeting

    Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients

    Eric Elkin1, Martin J. Bergman2, Tripthi Kamath3, Sarika Ogale3, Adam Turpcu3, Kristin King4, Jae Oh4, Monarch Shah1 and Max I. Hamburger5, 1ICON Clinical Research, San Francisco, CA, 2Taylor Hospital, Ridley Park, PA, 3Genentech, South San Francisco, CA, 4ICON Late Phase and Outcomes Research, San Francisco, CA, 5Rheumatology Associates, Melville, NY

    Background/Purpose: Results from randomized controlled trials indicate that about one-third of rheumatoid arthritis (RA) patients initially treated with anti-TNF agents do not respond, show a…
  • Abstract Number: 1422 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis

    Daisuke Kobayashi1, Satoshi Ito2, Akira Murasawa1, Ichiei Narita3 and Kiyoshi Nakazono1, 1Niigata Rheumatic Center, Shibata, Japan, 2Niigata Rheumatic Center, Niigata, Japan, 3Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

    Background/Purpose: Iguratimod is a newly-developed disease-modifying antirheumatic drug (DMARD) that was approved in Japan in September 2012. It has been reported to suppress tumor necrosis…
  • Abstract Number: 484 • 2013 ACR/ARHP Annual Meeting

    Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha  Agents In Rheumatoid Arthritis Patients

    Eric Elkin1, Max I. Hamburger2, Tripthi Kamath3, Sarika Ogale3, Adam Turpcu3, Jae Oh4, Kristin King4, Monarch Shah1 and Martin J. Bergman5, 1ICON Clinical Research, San Francisco, CA, 2Rheumatology Associates, Melville, NY, 3Genentech, South San Francisco, CA, 4ICON Late Phase and Outcomes Research, San Francisco, CA, 5Taylor Hospital, Ridley Park, PA

    Background/Purpose: Rheumatoid arthritis (RA) patients who have failed an anti-TNF agent as their first biologic agent have the option of switching to a second aTNF…
  • Abstract Number: 203 • 2013 ACR/ARHP Annual Meeting

    Belief In Self-Adjustability Of Medication Dosing Is Negatively Correlated With Medication Adherence In Patients With Rheumatoid Arthritis

    Wenxin Sun1, Dianne Carrol Tan Bautista2, Xiaohui Xin3, Yu Ting Saw3, Wee Boon Tan3, Kanchanadevi Balasubramaniam3, Wan Pin Lee4, Steve Thein Htay Oo3, Yin Bun Cheung2 and Julian Thumboo5, 1Duke-NUS Graduate Medical School, Singapore, Singapore, 2Center for Quantitative Medicine, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore, Singapore, 3Academic Clinical Programme, Division of Medicine, Singapore General Hospital, Singapore, Singapore, 4Operation and Performance Management, Singapore General Hospital, Singapore, Singapore, 5Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore

    Background/Purpose: Medication adherence in Rheumatoid Arthritis (RA) is reported to be generally low. This major problem needs to be addressed because it leads to reduced…
  • Abstract Number: 193 • 2013 ACR/ARHP Annual Meeting

    Physician Variability In Rheumatoid Patients Not Receiving Biologics Or Non-Biologic Dmards: Implications For Quality Reporting

    Dimitrios A. Pappas1, Lang Chen2, Leslie R. Harrold3, George W. Reed4, Joel M. Kremer5, Jeffrey D. Greenberg6 and Jeffrey R. Curtis7, 1Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 2Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Massachusetts Medical School, Worcester, MA, 4Corrona, LLC., Southborough, MA, 5Center for Rheumatology, Albany Medical College, Albany, NY, 6Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 7University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: Current quality of care guidelines recommend that all patients with Rheumatoid Arthritis (RA) be treated with biologic and/or non-biologic (nb) DMARDs. However, some RA…
  • Abstract Number: 2636 • 2012 ACR/ARHP Annual Meeting

    Understanding Why Treat-to-Target Strategies Are Difficult to Follow

    Liana Fraenkel1, Meaghan Cunningham2 and Paul Falzer3, 1Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 2Medicine, Yale University School of Medicine, New Haven, CT, 3Medicine, VA Connecticut Healthcare System, New Haven, CT

    Background/Purpose: Treat-to-target (T2T) refers to a set of decision strategies widely advocated for the optimal management of rheumatoid arthritis (RA). Despite considerable evidence that this…
  • Abstract Number: 387 • 2012 ACR/ARHP Annual Meeting

    Medication Choices and Medication Survival in a National Multicentre Community Based Rheumatoid Arthritis Cohort

    Lynden Roberts1, Kathleen Tymms2, Julien P. de Jager3, Geoffrey O. Littlejohn4, Hedley Griffiths5, Dave Nicholls6, Paul Bird7, Julie Hill8, Philip McCloud8, James C. Scott9, Jane Zochling10 and OPAL Consortium11, 1School of Medicine, James Cook University, Townsville, Australia, 2Canberra Rheumatology, Canberra, ACT, Australia, 3Suite 2, Osler House, Southport, Australia, 4Rheumatology, Monash Medical Center, Melbourne, Australia, 5Barwon Rheumatology Service, Geelong, Australia, 6Coast Joint Care, Maroochydore, Australia, 7Combined Rheumatology Practice, Sydney, Australia, 8Statistics, McCloud Consulting Group, Sydney, Australia, 9Medical Affairs, Roche Products Pty Limited, Sydney, Australia, 10Menzies Research Institute Tasmania, Hobart, Australia, 11Melbourne, Australia

    Background/Purpose: A sizeable body of high-quality research underpins our knowledge of the efficacy of various RA therapies. Outside the controlled environment of these clinical trials,…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology